JP2008535821A - 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 - Google Patents

過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 Download PDF

Info

Publication number
JP2008535821A
JP2008535821A JP2008503236A JP2008503236A JP2008535821A JP 2008535821 A JP2008535821 A JP 2008535821A JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008535821 A JP2008535821 A JP 2008535821A
Authority
JP
Japan
Prior art keywords
met
antibody
antagonist
cell
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535821A5 (https=
Inventor
モニカ コング−ベルトラン，
ダイネリ， エム． ウィックラマシンゲ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008535821(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2008535821A publication Critical patent/JP2008535821A/ja
Publication of JP2008535821A5 publication Critical patent/JP2008535821A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008503236A 2005-03-25 2006-03-24 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 Pending JP2008535821A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25
PCT/US2006/010850 WO2006104911A2 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012116934A Division JP2012232979A (ja) 2005-03-25 2012-05-22 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2008535821A true JP2008535821A (ja) 2008-09-04
JP2008535821A5 JP2008535821A5 (https=) 2009-04-09

Family

ID=37053941

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008503236A Pending JP2008535821A (ja) 2005-03-25 2006-03-24 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物
JP2012116934A Pending JP2012232979A (ja) 2005-03-25 2012-05-22 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012116934A Pending JP2012232979A (ja) 2005-03-25 2012-05-22 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物

Country Status (17)

Country Link
US (2) US7615529B2 (https=)
EP (1) EP1868648B1 (https=)
JP (2) JP2008535821A (https=)
KR (1) KR20080000613A (https=)
CN (1) CN101184506B (https=)
AU (1) AU2006229989B2 (https=)
BR (1) BRPI0611468A2 (https=)
CA (1) CA2599988A1 (https=)
ES (1) ES2539790T3 (https=)
IL (1) IL185708A (https=)
MX (1) MX2007011652A (https=)
NO (1) NO20075412L (https=)
NZ (1) NZ561211A (https=)
RU (1) RU2404193C2 (https=)
SG (1) SG159547A1 (https=)
WO (1) WO2006104911A2 (https=)
ZA (1) ZA200707953B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561211A (en) 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
KR20100135780A (ko) * 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
MX2011010166A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
US20130259878A1 (en) * 2010-10-20 2013-10-03 Oxford Biotherapeutics Ltd Antibodies
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
SG11201402485UA (en) * 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
AU2015229035B2 (en) 2014-03-14 2021-08-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
CN113150147A (zh) 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
MY192158A (en) 2016-09-14 2022-08-03 Abbvie Biotherapeutics Inc Anti-pd-1 antibodies and their uses
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN114478788B (zh) 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506327A (ja) * 1995-06-02 1999-06-08 ジェネンテック インコーポレーテッド 肝細胞増殖因子受容体拮抗剤とその使用法
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014772A3 (en) 1996-04-05 2009-05-27 Antonio Giordano Method for the diagnosis and prognosis of cancer
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
WO2005001486A1 (en) * 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
NZ561211A (en) 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
KR20080004514A (ko) 2005-03-25 2008-01-09 제넨테크, 인크. 폐암에서의 ｃ-ｍｅｔ 돌연변이

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506327A (ja) * 1995-06-02 1999-06-08 ジェネンテック インコーポレーテッド 肝細胞増殖因子受容体拮抗剤とその使用法
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6011057761; Ｃａｎｃｅｒ　Ｒｅｓ．，　６５［４］　（２００５　Ｆｅｂ）　ｐ．１４７９-８８． *
JPN6011057762; Ｇｅｎｅ，　２１５　（１９９８）　ｐ．１５９-１６９ *
JPN6011057763; Ｏｎｃｏｇｅｎｅ， Ｖｏｌ．９ Ｎｏ．７ （１９９４） ｐ．２０４５-２０５２ *
JPN6011057764; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ．，　Ｖｏｌ．２６９　Ｎｏ．３０　（１９９４）　ｐ．１９４５７-１９４６１ *
JPN6011057765; Ｓｃｉｅｎｃｅ，　Ｖｏｌ．２５４　Ｎｏ．５０３６　（１９９１）　ｐ．１３８２-１３８５ *
JPN6011057766; Ｏｎｃｏｇｅｎｅ，　Ｖｏｌ．１９　Ｎｏ．４９　（２０００）　ｐ．５６８０-５６８９ *

Also Published As

Publication number Publication date
CN101184506A (zh) 2008-05-21
WO2006104911A2 (en) 2006-10-05
US20100028337A1 (en) 2010-02-04
CA2599988A1 (en) 2006-10-05
US20060270594A1 (en) 2006-11-30
HK1109075A1 (en) 2008-05-30
EP1868648A2 (en) 2007-12-26
AU2006229989B2 (en) 2012-02-02
BRPI0611468A2 (pt) 2010-09-08
IL185708A (en) 2014-11-30
NZ561211A (en) 2011-03-31
MX2007011652A (es) 2007-11-14
EP1868648B1 (en) 2015-04-15
AU2006229989A1 (en) 2006-10-05
JP2012232979A (ja) 2012-11-29
ES2539790T3 (es) 2015-07-06
US7615529B2 (en) 2009-11-10
NO20075412L (no) 2007-12-21
IL185708A0 (en) 2008-01-06
RU2007139452A (ru) 2009-04-27
US8536118B2 (en) 2013-09-17
ZA200707953B (en) 2009-06-24
CN101184506B (zh) 2013-07-17
WO2006104911A3 (en) 2007-02-22
SG159547A1 (en) 2010-03-30
KR20080000613A (ko) 2008-01-02
RU2404193C2 (ru) 2010-11-20

Similar Documents

Publication Publication Date Title
US7615529B2 (en) Methods and compositions for modulating hyperstabilized c-met
US12583937B2 (en) Compositions and methods for the diagnosis and treatment of tumor
JP5196654B2 (ja) 腫瘍の診断と治療のための組成物と方法
TW201142295A (en) Compositions and methods for the diagnosis and treatment of tumor
JP2013511993A5 (https=)
JP2018512597A (ja) 突然変異体スムースンド及びその使用方法
US20130058960A1 (en) Compositions and methods for the diagnosis and treatment of tumor
HK1109075B (en) Methods and compositions for modulating hyperstabilized c-met

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130716